Literature DB >> 15188130

Prognostic parameters of endometrial carcinoma.

Jaime Prat1.   

Abstract

Endometrial carcinoma is the most common malignant tumor of the female genital tract in the Western world. Approximately 80% of cases are well- to moderately differentiated (endometrioid) adenocarcinomas, which are confined to the uterine corpus at diagnosis, and thus most can be cured. Conversely, high-grade (ie, clear cell and serous) carcinomas account for only 15% to 20% of cases and show marked nuclear atypia. These tumors usually invade the myometrium and may extend beyond the uterus at the time of hysterectomy. In addition to clinical and morphological differences, these 2 groups of endometrial carcinomas differ in their pathogenesis. Whereas prognosis in the latter group is generally poor, the pathologist's role in establishing the outcome in the former group is crucial. Furthermore, it has become progressively apparent that both groups overlap to some extent, making the dualistic model a guideline at best. Over the last 2 decades, several studies have demonstrated the prognostic importance of various key surgical and pathological parameters, including histological type, histological grade, surgical-pathological stage, depth of myometrial invasion, vascular invasion, and cervical involvement. This review presents the most important prognostic factors of endometrial carcinomas from the pathologist's viewpoint, and attempts to clarify existing conflicts in the classification and diagnosis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188130     DOI: 10.1016/j.humpath.2004.02.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  59 in total

1.  Clinical significance of Sam68 expression in endometrial carcinoma.

Authors:  Qingying Wang; Yue Li; Jianhong Zhou; Jie Liu; Jinlong Qin; Feng Xing; Jiawen Zhang; Jiajing Cheng
Journal:  Tumour Biol       Date:  2015-01-21

2.  Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers.

Authors:  Aung Ko Win; James G Dowty; Yoland C Antill; Dallas R English; John A Baron; Joanne P Young; Graham G Giles; Melissa C Southey; Ingrid Winship; Lara Lipton; Susan Parry; Stephen N Thibodeau; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Noralane M Lindor; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

3.  Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.

Authors:  Liuyan Jiang; Anais Malpica; Michael T Deavers; Ming Guo; Luisa Lina Villa; Gerard Nuovo; Maria J Merino; Elvio G Silva
Journal:  Int J Gynecol Pathol       Date:  2010-03       Impact factor: 2.762

4.  Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization.

Authors:  Wanja Kildal; Francesca Micci; Bjørn Risberg; Vera M Abeler; Gunnar B Kristensen; Sverre Heim; Håvard E Danielsen
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

Review 5.  Molecular staging of gynecological cancer: What is the future?

Authors:  Pratibha S Binder; Jaime Prat; David G Mutch
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2015-03-04       Impact factor: 5.237

6.  Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Susanna Syriac; Heidi Godoy; Nefertiti Dupont; Song Liu; Kunle Odunsi
Journal:  Gynecol Oncol       Date:  2011-10-19       Impact factor: 5.482

7.  Allelic loss at TP53 in metastatic human endometrial carcinomas.

Authors:  Wiktor Szewczuk; Danuta Skomra; Marek Cybulski; Dorota Przadka-Rabaniuk; Agata Filip; Maciej Jóźwik; Piotr Olcha; Albert Roessner; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2009-06-30       Impact factor: 5.150

8.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

9.  Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?

Authors:  Nina Bassarak; Thomas Blankenstein; Ansgar Brüning; Darius Dian; Florian Bergauer; Klaus Friese; Ioannis Mylonas
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

10.  Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model.

Authors:  Sandra Karlsson; Björn Olsson; Karin Klinga-Levan
Journal:  Cancer Cell Int       Date:  2009-05-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.